Patient‐centered benefit–risk assessment in duchenne muscular dystrophy

This study quantified caregiver and patient preferences for a therapeutic agent with demonstrated pulmonary benefits for Duchenne muscular dystrophy (DMD). Caregiver and patient differences were also explored.

[1]  J. Bridges,et al.  Developing a Patient-Centered Benefit-Risk Survey: A Community-Engaged Process. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[2]  Y. Rideau,et al.  Respiratory function in the muscular dystrophies , 1981, Muscle & nerve.

[3]  Joanna Coast,et al.  Estimating preferences for a dermatology consultation using Best-Worst Scaling: Comparison of various methods of analysis , 2008, BMC medical research methodology.

[4]  R. Abresch,et al.  Profiles of neuromuscular diseases. Becker's muscular dystrophy. , 1995, American journal of physical medicine & rehabilitation.

[5]  Telba Irony,et al.  Incorporating patient-preference evidence into regulatory decision making , 2014, Surgical Endoscopy.

[6]  S. Inkley,et al.  Pulmonary function in Duchenne muscular dystrophy related to stage of disease. , 1974, The American journal of medicine.

[7]  D. Collins.  Pretesting survey instruments: An overview of cognitive methods , 2003, Quality of Life Research.

[8]  R. Califf,et al.  Engaging Patients Across the Spectrum of Medical Product Development: View From the US Food and Drug Administration. , 2015, JAMA.

[9]  V. Ricotti,et al.  Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[10]  Elizabeth T. Kinter,et al.  Things are Looking up Since We Started Listening to Patients , 2008, The patient.

[11]  John F P Bridges,et al.  A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy. , 2014, Clinical therapeutics.

[12]  B. Alman,et al.  Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade , 2006, Neuromuscular Disorders.

[13]  Malcolm Kohler,et al.  Quality of life, physical disability, and respiratory impairment in Duchenne muscular dystrophy. , 2005, American journal of respiratory and critical care medicine.

[14]  John F P Bridges,et al.  Caregiver Preferences for Emerging Duchenne Muscular Dystrophy Treatments: A Comparison of Best-Worst Scaling and Conjoint Analysis , 2015, The Patient - Patient-Centered Outcomes Research.

[15]  J. Louviere,et al.  Some probabilistic models of best, worst, and best–worst choices , 2005 .

[16]  Maarten J. IJzerman,et al.  Why Should Regulators Consider Using Patient Preferences in Benefit-risk Assessment? , 2013, PharmacoEconomics.

[17]  T. Flynn.  Valuing citizen and patient preferences in health: recent developments in three types of best–worst scaling , 2010, Expert review of pharmacoeconomics & outcomes research.

[18]  J. Louviere,et al.  Determining the Appropriate Response to Evidence of Public Concern: The Case of Food Safety , 1992 .

[19]  C. Angelini.  The role of corticosteroids in muscular dystrophy: A critical appraisal , 2007, Muscle & nerve.

[20]  S. Greenfield,et al.  Women's colposcopy experience and preferences: a mixed methods study , 2008, BMC women's health.

[21]  Deborah Marshall,et al.  Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[22]  Elizabeth T. Kinter,et al.  A Comparison of Two Experimental Design Approaches in Applying Conjoint Analysis in Patient-Centered Outcomes Research , 2012, The Patient: Patient-Centered Outcomes Research.

[23]  J Coast,et al.  Preferences for aspects of a dermatology consultation , 2006, The British journal of dermatology.

[24]  R. Griggs,et al.  Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids 2–4 April 2004, Naarden, The Netherlands , 2004, Neuromuscular Disorders.

[25]  Terry N Flynn,et al.  Using Best-Worst Scaling Choice Experiments to Measure Public Perceptions and Preferences for Healthcare Reform in Australia , 2010, The patient.

[26]  J. Louviere,et al.  A comparison of importance weights and willingness-to-pay measures derived from choice-based conjoint, constant sum scales and best-worst scaling , 2008 .

[27]  Richard Emsley,et al.  Applying Best-Worst scaling methodology to establish delivery preferences of a symptom supportive care intervention in patients with lung cancer. , 2012, Lung cancer.

[28]  T. Flynn,et al.  USING BEST-WORST SCALING IN HORIZON SCANNING FOR HEPATOCELLULAR CARCINOMA TECHNOLOGIES , 2012, International Journal of Technology Assessment in Health Care.

[29]  J. Marti.  A best-worst scaling survey of adolescents' level of concern for health and non-health consequences of smoking. , 2012, Social science & medicine.

[30]  K. Flanigan,et al.  How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration , 2015, Orphanet Journal of Rare Diseases.

[31]  R. Finkel,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management , 2010, The Lancet Neurology.

[32]  K. Carlsen,et al.  Lung function in children with Duchenne's muscular dystrophy. , 2001, Respiratory medicine.